Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Study sponsor: Revolution Medicines, Inc. · RVMD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-07-03Actual
Enrollment · participants47Actual
Source updated2026-01-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.